1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2013. http://www.goldcopd.org/ . Accessed 9 Jan 2014.
2. Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Resp Crit Care Med. 2013;187(4):347–65.
3. US Food and Drug Administration. FDA approves Anoro Ellipta to treat chronic obstructive pulmonary disease. 2013. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm379057.htm . Accessed 10 Jan 2014.
4. GlaxoSmithKline Inc. Anoro Ellipta approved for COPD in Canada [media release]. 2014. http://www.firstwordpharma.com/node/1177487?tsid=28®ion_id=3#axzz2qDDGAfxx . Accessed 13 Jan 2014.
5. Theravance Inc, GlaxoSmithKline plc. GlaxoSmithKline to increase its shareholding in Theravance [media release]. 2010. http://www.gsk.com/media/press-releases/2010/glaxosmithkline-to-increase-its-shareholding-in-theravance.html . Accessed 9 Jan 2014.